Researchers have demonstrated that a single infusion of an experimental gene-editing therapy could provide long-lasting protection against heart disease by permanently lowering LDL cholesterol levels.
The small clinical trial tested VERVE-201, a one-time genetic treatment developed by CRISPR Therapeutics and Vertex Pharmaceuticals. Scientists used CRISPR gene-editing technology to modify patients' liver cells, disabling a gene that increases LDL production. The results showed sustained reductions in "bad" cholesterol that persisted months after the single infusion.
LDL cholesterol accumulates in arteries and drives heart attack and stroke risk. Current treatments require patients to take statins daily or receive regular injections of newer drugs like PCSK9 inhibitors. Those medications work but demand strict adherence. A one-time intervention represents a fundamentally different approach.
In the trial, participants experienced LDL reductions without the side effects typical of aggressive cholesterol management. One expert quoted in reporting called the results potentially "curative" rather than merely therapeutic, reflecting the permanent nature of genetic modification.
The technology targets PCSK9, a protein that regulates cholesterol removal from the bloodstream. By editing the gene responsible for this protein, scientists essentially reprogrammed patients' liver cells to process cholesterol more efficiently. This addresses the root cause rather than managing symptoms.
However, significant hurdles remain before this becomes standard care. The trial involved only a handful of patients. Regulators must confirm safety over decades, not just months. Long-term effects remain unknown. Gene-editing therapies also carry theoretical risks, including off-target genetic changes or unintended immune responses.
The therapy targets familial hypercholesterolemia patients first, people with genetic predispositions toward dangerously high cholesterol. For them, this approach could be transformative. Broader applications